A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

NCT07388602 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: SCTC21C
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Cyclophosphamide

Sponsor

Sinocelltech Ltd.